AE Wealth Management’s Ginkgo Bioworks DNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-595
Closed -$30.7K 1352
2023
Q4
$30.7K Buy
595
+4
+0.7% +$245 ﹤0.01% 2002
2023
Q3
$42.8K Sell
591
-3
-0.5% -$240 ﹤0.01% 1886
2023
Q2
$44.2K Buy
594
+64
+12% +$3.79K ﹤0.01% 1842
2023
Q1
$28.2K Sell
530
-38
-7% -$2.41K ﹤0.01% 1837
2022
Q4
$38.4K Buy
568
+182
+47% +$16.7K ﹤0.01% 1759
2022
Q3
$48K Buy
+386
New +$46K ﹤0.01% 1689

Other funds holding DNA

AE Wealth Management's DNA Position: Q1 2024 in Review

AE Wealth Management sold out of Ginkgo Bioworks (DNA) in Q1 2024, closing a stake of 595 shares — an estimated $30.7K sold.

AE Wealth Management first reported a position in DNA in Q3 2022 and held it in 6 quarters. The position peaked at $48K in Q3 2022. 342 funds tracked by Wall St. Rank hold DNA as of Q1 2024.

  • AE Wealth Management reported no remaining Ginkgo Bioworks position as of Q1 2024 after selling out during the quarter.
  • AE Wealth Management sold 595 Ginkgo Bioworks shares in Q1 2024, an estimated $30.7K.
  • AE Wealth Management first reported a position in Ginkgo Bioworks in Q3 2022 and held it in 6 quarters.
  • AE Wealth Management's Ginkgo Bioworks position peaked at $48K in Q3 2022.
  • 342 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2024.

Based on AE Wealth Management's 13F filing for Q1 2024, filed 15 May 2024.